ClinConnect ClinConnect Logo
Search / Trial NCT07126171

A Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever

Launched by JIANGSU KANION PHARMACEUTICAL CO., LTD · Aug 10, 2025

Trial Information

Current as of October 14, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Reduning Injection to see if it is safe and effective in treating chikungunya fever, a viral illness that causes fever, joint pain, rash, and other symptoms. The goal is to find out whether this treatment can help people recover faster and feel better during the illness.

Adults between 18 and 70 years old who have recently developed chikungunya fever symptoms—such as fever lasting less than 48 hours, a temperature of at least 38°C (100.4°F), and moderate or worse symptoms like headache, muscle or joint pain, nausea, or rash—may be eligible to join. People with other infections like dengue or COVID-19, certain health conditions, pregnant or breastfeeding women, and those with allergies to the study drugs are not eligible. Participants will be closely monitored for their health and response to the treatment during the study. This trial is not yet open for enrollment, but if you or a loved one fits the criteria and is interested, it may be worth discussing with your healthcare provider.

Gender

ALL

Eligibility criteria

  • Inclusion criteria:
  • 1. Meet the diagnostic criteria for chikungunya fever (can be randomly selected based on suspected cases);
  • 2. Fever duration ≤ 48 hours, and at the time of consultation, axillary temperature ≥ 38.0℃ (if antipyretic drugs have been taken, the axillary temperature must be ≥ 38.0℃ 4 hours or later after taking the drugs);
  • 3. The first symptoms of chikungunya fever other than fever have a duration ≤ 72 hours;
  • 4. At the time of consultation, have one or more of the following symptoms: headache, back pain or generalized muscle pain, nausea and vomiting, joint pain, joint swelling, joint stiffness, rash, and the severity is moderate or above;
  • 5. Age between 18 and 70 years old (including both ends), gender not restricted;
  • 6. Provide informed consent and sign the informed consent form.
  • Exclusion criteria:
  • 1. Those diagnosed with dengue fever, alphavirus infection, influenza, novel coronavirus infection, infectious erythema, post-infection arthritis (including rheumatic fever), scarlet fever, rickettsial diseases (typhus, scrub typhus), measles, drug-induced rash, etc.;
  • 2. Acute, chronic stages of chikungunya fever and high-risk populations;
  • 3. Those with severe primary diseases of the cardiovascular, liver, kidney and hematopoietic systems;
  • 4. Those with chronic arthritis;
  • 5. Those with immunodeficiency (such as AIDS patients, those with long-term use of corticosteroids or other immunosuppressive drugs resulting in weakened immune function);
  • 6. Those with obesity (BMI ≥ 30 kg/m2) or weight \< 40 kg;
  • 7. Those suspected or confirmed to have alcohol addiction, drug abuse history, or those with cognitive impairment, severe mental illness and unable to cooperate with the clinical study;
  • 8. Pregnant women or those preparing for pregnancy within 6 months, and lactating women;
  • 9. Those with allergic constitution, such as history of allergy to two or more drugs or foods, or those known to be allergic to the drugs used in this study and the ingredients of acetaminophen tablets;
  • 10. Those who participated in any clinical study within 3 months before the screening examination;
  • 11. Those judged by the researcher to be not suitable to participate in this clinical study.

About Jiangsu Kanion Pharmaceutical Co., Ltd

Jiangsu Kanion Pharmaceutical Co., Ltd. is a leading pharmaceutical company based in China, dedicated to the research, development, manufacturing, and marketing of innovative healthcare solutions. Established with a commitment to advancing therapeutic options, Kanion specializes in a wide range of pharmaceutical products, including traditional Chinese medicine, chemical drugs, and biopharmaceuticals. The company is recognized for its robust pipeline, adherence to rigorous quality standards, and investment in cutting-edge research, positioning it as a key player in both domestic and international markets. With a focus on improving patient outcomes, Jiangsu Kanion Pharmaceutical continues to contribute significantly to the global healthcare landscape through strategic collaborations and clinical trials aimed at delivering safe and effective therapies.

Locations

Guangzhou, Guangdong, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported